Literature DB >> 24247741

Significance of histological crescent formation in patients with diffuse proliferative lupus nephritis.

Shasha Chen1, Zheng Tang, Yiyan Zhang, Zhengzhao Liu, Haitao Zhang, Weixin Hu, Zhihong Liu.   

Abstract

BACKGROUND: Although crescentic nephritis is not rare in diffuse proliferative lupus nephritis (DPLN), little is known about the clinicopathological features in DPLN with crescents worldwide. This study was undertaken to investigate the clinicopathological features and outcome of Chinese DPLN patients with different degrees of crescents.
METHODS: 520 DPLN patients with more than 10% histological crescents (cDPLN) were enrolled in this retrospective study. They were divided into three groups: group 1 (10%≤ crescents <25%, n = 240), group 2 (25%≤ crescents <50%, n = 160), and group 3 (crescents ≥50%, n = 120). Another 100 patients without histological crescents were enrolled as a control group. Clinicopathological features, treatment responses, and outcomes were compared among the four groups.
RESULTS: There were 450 (86.6%) females and 70 (13.4%) males with an average age of 31.7 ± 11.4 years. Compared with the control group, cDPLN patients had shorter lupus nephritis duration (20.7 ± 34.1 vs. 30.4 ± 48.9 months), higher prevalence of rapidly progressive glomerulonephritis syndrome (21.8%), and gross hematuria (26.7%). Laboratory findings indicated more severe hypoproteinemia, hyperlipidemia, and renal insufficiency; heavier proteinuria and microscopic hematuria; higher tubular injury parameters, and lower serological activity in crescentic groups. Histologically, cDPLN patients have severe glomerular and tubulointerstitial lesions as well as extensive leukocyte infiltration together with a lesser degree of immune complex deposition. The proportion of death, end-stage renal disease, and treatment failure correlates positively with the degree of histological crescents.
CONCLUSIONS: cDPLN patients with acute onset and short disease duration mostly show severe renal manifestations, less extrarenal organ involvement, lower serological activity, serious capillary necrosis, severe tubulointerstitial inflammation, atrophy and fibrosis, prominent leukocyte infiltration, less glomerular immune complex deposition, poor treatment response, and worse renal outcome.
© 2013 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2013        PMID: 24247741     DOI: 10.1159/000356184

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  10 in total

1.  Successful treatment of severe crescentic lupus nephritis by multi-target therapy using tacrolimus and mycophenolate mofetil.

Authors:  Kaori Mochizuki; Ken Kayakabe; Keiju Hiromura; Masayasu Ando; Noriyuki Sakurai; Hidekazu Ikeuchi; Toru Sakairi; Yoriaki Kaneko; Akito Maeshima; Yoshihisa Nojima
Journal:  CEN Case Rep       Date:  2014-10-12

2.  Correlation between endocapillary proliferative and nephrotic-range proteinuria in children with Henoch-Schönlein purpura nephritis.

Authors:  Xiao-Qing Yang; Yan-Jie Huang; Wen-Sheng Zhai; Xian-Qing Ren; Qing-Yin Guo; Xia Zhang; Meng Yang; Jian Zhang; Ying Ding; Shan Zhu; Tatsuo Yamamoto; Yuan Sun
Journal:  Pediatr Nephrol       Date:  2018-11-10       Impact factor: 3.714

Review 3.  Treatment of severe lupus nephritis: the new horizon.

Authors:  Tak Mao Chan
Journal:  Nat Rev Nephrol       Date:  2014-11-25       Impact factor: 28.314

4.  Glomerular necrotic lesions and long-term outcomes among patients with proliferative lupus nephritis.

Authors:  Abdulkareem Alsuwaida; Sufia Husain; Mohammed Al Ghonaim; Saad Alobaili; Jamal Alwakeel; Riyadh Al Sehli; Akram Askar; Ahmad Tarakji; Hala Kfoury
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

5.  Efficacy and safety of cyclophosphamide combined with mycophenolate mofetil for induction treatment of class IV lupus nephritis.

Authors:  Jian Sun; Hao Zhang; Ying Ji; Ming Gui; Bin Yi; Jianwen Wang; Juan Jiang
Journal:  Int J Clin Exp Med       Date:  2015-11-15

6.  Pathological spectrums and renal prognosis of severe lupus patients with rapidly progressive glomerulonephritis.

Authors:  Shasha Chen; Hao Chen; Zhengzhao Liu; Haitao Zhang; Weixin Hu; Zheng Tang; Zhihong Liu
Journal:  Rheumatol Int       Date:  2014-10-04       Impact factor: 2.631

7.  Clinicopathological correlation in asian patients with biopsy-proven lupus nephritis.

Authors:  Bancha Satirapoj; Pamila Tasanavipas; Ouppatham Supasyndh
Journal:  Int J Nephrol       Date:  2015-03-19

8.  What is new in the management of rapidly progressive glomerulonephritis?

Authors:  George H B Greenhall; Alan D Salama
Journal:  Clin Kidney J       Date:  2015-02-19

9.  Clinicopathological correlations in lupus nephritis; a single center experience.

Authors:  Hamid Nasri; Ali Ahmadi; Azar Baradaran; Ali Momeni; Parto Nasri; Saeed Mardani; Mahmood Rafieian-Kopaei; Muhammed Mubarak
Journal:  J Nephropathol       Date:  2014-04-12

Review 10.  Management of lupus nephritis: a systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations.

Authors:  Myrto Kostopoulou; Antonis Fanouriakis; Kim Cheema; John Boletis; George Bertsias; David Jayne; Dimitrios T Boumpas
Journal:  RMD Open       Date:  2020-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.